Ustekinumab, a humanised monoclonal antibody, was well tolerated and demonstrated acceptable remission rates and drug persistence at 1 year in patients with refractory ulcerative colitis (UC). "This ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
Johnson & Johnson's Stelara posts positive 3-year data in ulcerative colitis as competition heats up
Since hitting the market in 2009, Johnson & Johnson’s blockbuster drug Stelara has made a habit of exceeding analyst expectations. There was no better example than last year when it overcame ...
Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA ...
“Despite recent substantial therapeutic gains, many patients living with ulcerative colitis still struggle to find lasting relief from their disease symptoms, especially without the use of steroids ...
SPRING HOUSE, Pa., July 9, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA (R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback